DNA-PK Inhibition Sustains the Antitumor Innate Immune Response in Small Cell Lung Cancer

Authors

Caterina De Rosa
Floriana Morgillo
Luisa Amato
Francesca Iommelli
Viviana De Rosa
Virginia Tirino
Federica Papaccio
Concetta Tuccillo
Gaetano Di Guida
Domenico Michele D'Angiolella
Alessandra Di Liello
Silvia Zappavigna
Michele Caraglia
Antonio Gambardella
Valerio Nardone
Kavya Ramkumar
Qi Wang
Jing Wang
Ferdinando De Vita
Davide Ciardiello
Erika Martinelli
Teresa Troiani
Stefania Napolitano
Giulia Martini
Alberto Servetto
Lauren Averett Byers
Fortunato Ciardiello
Carminia Maria Della Corte

Publication Date

3-21-2025

Journal

iScience

DOI

10.1016/j.isci.2025.111943

PMID

40034862

PMCID

PMC11875153

PubMedCentral® Posted Date

2-1-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with limited treatment options. Patients often respond well to initial chemo-immunotherapy but relapse quickly, necessitating new strategies to enhance immune responsiveness. Recent research explores combining DNA-damaging therapies with immunotherapy to activate the STING pathway and improve the antitumor immune response. The addition of DNA Damage Repair (DDR) inhibitors, such as DNA-PKcs inhibitors, after chemotherapy has shown promise in activating innate immune sensors and enhancing CD8

Keywords

Molecular biology, Cell biology, Cancer

Published Open-Access

yes

Recommended Citation

De Rosa, Caterina; Morgillo, Floriana; Amato, Luisa; et al., "DNA-PK Inhibition Sustains the Antitumor Innate Immune Response in Small Cell Lung Cancer" (2025). Faculty, Staff and Student Publications. 2667.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/2667